PRESENTATION
A 23-year-old man was presented with slowly progressive bilateral decreasing vision over the past 3 years. He had no remarkable medical, surgical or family history of ocular or systemic disease. Best-corrected visual acuity (BCVA) was 20/200 in both eyes with -1-0.75×90 and -1.50-0.50×90 correction in the right and left eyes, respectively. Anterior segment examination revealed diffuse neovascularization of iris (NVI) in both eyes [ Figure 1 ]. Diffuse capillary non-perfused areas associated with occluded retinal vessels in both eyes, and fibrovascular membrane with traction on the macula in the left eye were present in dilated fundus examination [ Figures 2 and 3] . Moreover, on wide field fluorescein angiography (FAG), extensive capillary non-perfused areas, occluded vessels, and retinal artery narrowing were observed [ Figures 4 and 5] . A complete systemic workup including detailed thrombophilia factors was requested among which a reduced level of circulating anti-thrombin III was significant. The patient was managed by pan-retinal laser photocoagulation (PRP) bilaterally in addition to intravitreal bevacizumab injection in the right eye.
DISCUSSION
Anti-thrombin III is a potent inhibitor of reactions in the coagulation cascade. Its main duty is to virtually inhibit all coagulation enzymes to some extent. Congenital anti-thrombin III deficiency is an autosomal dominant disorder in which an individual inherits one copy of a defective gene. This condition leads to an increased risk of venous and arterial thrombosis with onset of clinical manifestations typically appearing in young adulthood. [1, 2] Acquired anti-thrombin III (AT III) deficiency has been reported in metabolic acidosis, hyper-lipoproteinemias, chronic liver diseases especially liver cirrhosis, active inflammatory bowel diseases, nephrotic syndrome, hemodialysis and disseminated intravascular coagulation. [3] Anti-thrombin deficiency is associated with a 5 to 50-fold increased risk for venous thrombosis. [4] Since the average age in patients affected by retinal vein occlusion (RVO) is 65, [5] the majority of RVO cases are mainly secondary to underlying cardiovascular diseases. [6] Although there is no consensus, it seems rational to refer patients with central RVO for thrombophilia screening if they are younger than 50 years of age. [7] Herein, we reported a patient with severe retinal ischemia secondary to multiple RVO with anti-thrombin III deficiency to emphasize the importance of detection of thrombophilia in cases of vein occlusion particularly in young subjects. Ophthalmologists play a key role in approaching such cases by uncovering systemic associations and preventing vision and life-threatening conditions. 
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